Reasons Why Investors Should Consider Betting on PGEN Stock

Image Source: Zacks Investment Research

Papzimeos Is Driving Rapid Revenue Growth

Papzimeos has demonstrated strong early commercial momentum since its launch in August 2025. In the second quarter of 2026, the company recorded product revenues of $53.3 million, more than doubling sequentially. For the first six months of 2026, the product generated $75.1 million of revenues.

Notably, the rapid revenue ramp translated into quarterly profitability, with Precigen reporting $20.1 million in net income in the second quarter compared with a $26.6 million net loss in the year-ago quarter. Rising patient hub enrollment and expanding adoption across major medical centers and community practices indicate that the product is gaining traction beyond the initial launch phase.

Market Exclusivity Provides Revenue Protection for PGEN

Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection gives Precigen an opportunity to establish a durable commercial franchise before potential competitors enter the market.

International Expansion Adds Long-Term Upside for PGEN

Precigen is pursuing additional growth opportunities outside the United States. The company’s marketing authorization application submitted to the European Medicines Agency in November 2025 is currently under review. Approval in Europe could provide another source of revenue growth. A redosing study is also underway, which could expand the product’s long-term treatment opportunity if supported by clinical results.

PRGN-2009 Provides Pipeline Optionality for PGEN

Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. PRGN-2009 is an investigational AdenoVerse immunotherapy being developed to activate the immune system and target HPV-associated cancers. The candidate is currently being evaluated in phase II clinical studies in patients with newly diagnosed HPV-associated oropharyngeal cancer. In parallel, Precigen is conducting a multicenter phase II study evaluating PRGN-2009 in combination with Merck & Co’s MRK Keytruda (pembrolizumab) in patients with recurrent or metastatic cervical cancer. Keytruda, MRK’s blockbuster drug, is approved for several types of cancers globally.

Although the candidate remains at the clinical stage and carries development risk, its progress could provide an additional source of long-term value and further validate Precigen’s HPV-focused technology. The company plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.

PGEN's Zacks Rank & Estimates

Precigen currently sports a Zacks Rank #1 (Strong Buy). Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents.

Other Stocks to Consider

Some other top-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX, currently sporting a Zacks Rank #1, while AC Immune ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 43.7% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 17.9% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research